TY  - GEN
AB  - c-Myc is a key transcription factor regulating hematopoiesis, and its overexpression is common in leukemia. c-Myc stability is controlled by phosphorylation at serine 62 (S62) and threonine 58 (T58), influencing protein degradation. This dissertation demonstrates that elevated c-Myc levels in lymphoid and myeloid leukemia are linked to increased protein stability and altered phosphorylation at these sites. Mechanisms include constitutive activation of upstream signaling and deregulation of degradation-promoting proteins. Overexpression of AXIN1 in a mouse lymphoma model delayed tumor onset, supporting strategies to target c-Myc stability. These findings identify aberrant c-Myc stabilization as a therapeutic target in leukemia.
AD  - Oregon Health and Science University
AU  - Tibbitts, Deanne
DA  - 2011
DO  - 10.6083/M45B00FN
DO  - DOI
ED  - Sears, Rosalie
ED  - Stork, Phillip
ED  - Mentor
ED  - Chair
ID  - 671
KW  - Precursor Cell Lymphoblastic Leukemia-Lymphoma
KW  - Proto-Oncogene Proteins c-myc
KW  - Phosphorylation
KW  - Leukemia
KW  - Protein Stability
KW  - Leukemia, Myeloid, Acute
KW  - Axin Protein
KW  - lymphoblastic leukemia
KW  - myc proteins
L1  - https://digitalcollections.ohsu.edu/record/671/files/672_etd.pdf
L2  - https://digitalcollections.ohsu.edu/record/671/files/672_etd.pdf
L4  - https://digitalcollections.ohsu.edu/record/671/files/672_etd.pdf
LK  - https://digitalcollections.ohsu.edu/record/671/files/672_etd.pdf
N2  - c-Myc is a key transcription factor regulating hematopoiesis, and its overexpression is common in leukemia. c-Myc stability is controlled by phosphorylation at serine 62 (S62) and threonine 58 (T58), influencing protein degradation. This dissertation demonstrates that elevated c-Myc levels in lymphoid and myeloid leukemia are linked to increased protein stability and altered phosphorylation at these sites. Mechanisms include constitutive activation of upstream signaling and deregulation of degradation-promoting proteins. Overexpression of AXIN1 in a mouse lymphoma model delayed tumor onset, supporting strategies to target c-Myc stability. These findings identify aberrant c-Myc stabilization as a therapeutic target in leukemia.
PB  - Oregon Health and Science University
PY  - 2011
T1  - Characterization of aberrant c-Myc phosphorylation and stability in acute myeloid and lymphoblastic leukemia
TI  - Characterization of aberrant c-Myc phosphorylation and stability in acute myeloid and lymphoblastic leukemia
UR  - https://digitalcollections.ohsu.edu/record/671/files/672_etd.pdf
Y1  - 2011
ER  -